Management of High Grade Dysplasia patients
Cancer Alliance | National | ||
---|---|---|---|
Number of High Grade Dysplasia patients in audit | 13 | 1120 | |
Cancer Alliance | National | ||
Method of Diagnosis | |||
– First diagnosis confirmed by second pathologist | N/A | 100.0% | 90.0% |
Treatment planning | |||
– HGD plan discussed at MDT | N/A | 100.0% | 93.0% |
– Treatment plan for active treatment | N/A | 100.0% | 82.0% |
First treatment | |||
– Endoscopic therapy (such as endoscopic resection) | N/A | 85.7% | 78.0% |
– Surveillance | N/A | 0.0% | 11.0% |
NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.
Management of oesophago-gastric cancer patients
Organisation | National | ||
---|---|---|---|
Number of oesophago-gastric (OG) cancer patients in audit | 184 | 19,865 | |
Case ascertainment for OG cancer (%) | 85-100% | ||
Method of Diagnosis | |||
– Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations |
25 | 12.4% | 13.1% |
– Patients with referral source reported as unknown | 0 | 0.0% | 1.4% |
Pre-treatment staging of cancer | |||
– Patients having staging CT scan recorded | 154 | 83.7% | 94.0% |
Treatment planning | |||
– Patients having a plan for curative treatment | 70 | 38.0% | 37.2% |
– Patients having a plan for non-curative treatment | 114 | 62.0% | 62.8% |
– Patients with non-curative plans having chemotherapy or radiotherapy | 44 | 38.6% | 34.7% |